Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125,012 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, Chen J, Zhang H, Niu Z, Fan Q, Lin L, Gu K, Liu Y, Ba Y, Miao Z, Jiang X, Zeng M, Chen J, Fu Z, Gan L, Wang J, Zhan X, Liu T, Li Z, Shen L, Shu Y, Zhang T, Yang Q, Zou J; ESCORT Study Group. Huang J, et al. Among authors: zhang t, zhang h, zhang y. Lancet Oncol. 2020 Jun;21(6):832-842. doi: 10.1016/S1470-2045(20)30110-8. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416073 Clinical Trial.
Constraints on Heavy Decaying Dark Matter from 570 Days of LHAASO Observations.
Cao Z, Aharonian F, An Q, Axikegu, Bai LX, Bai YX, Bao YW, Bastieri D, Bi XJ, Bi YJ, Cai JT, Cao Z, Chang J, Chang JF, Chen ES, Chen L, Chen L, Chen L, Chen MJ, Chen ML, Chen QH, Chen SH, Chen SZ, Chen TL, Chen Y, Cheng HL, Cheng N, Cheng YD, Cui SW, Cui XH, Cui YD, D'Ettorre Piazzoli B, Dai BZ, Dai HL, Dai ZG, Danzengluobu, Della Volpe D, Duan KK, Fan JH, Fan YZ, Fan ZX, Fang J, Fang K, Feng CF, Feng L, Feng SH, Feng XT, Feng YL, Gao B, Gao CD, Gao LQ, Gao Q, Gao W, Gao WK, Ge MM, Geng LS, Gong GH, Gou QB, Gu MH, Guo FL, Guo JG, Guo XL, Guo YQ, Guo YY, Han YA, He HH, He HN, He SL, He XB, He Y, Heller M, Hor YK, Hou C, Hou X, Hu HB, Hu Q, Hu S, Hu SC, Hu XJ, Huang DH, Huang WH, Huang XT, Huang XY, Huang Y, Huang ZC, Ji XL, Jia HY, Jia K, Jiang K, Jiang ZJ, Jin M, Kang MM, Ke T, Kuleshov D, Levochkin K, Li BB, Li C, Li C, Li F, Li HB, Li HC, Li HY, Li J, Li J, Li J, Li K, Li WL, Li XR, Li X, Li X, Li YZ, Li Z, Li Z, Liang EW, Liang YF, Lin SJ, Liu B, Liu C, Liu D, Liu H, Liu HD, Liu J, Liu JL, Liu JS, Liu JY, Liu MY, Liu RY, Liu SM, Liu W, Liu Y, Liu YN, Long WJ, Lu R, Luo Q, Lv HK, Ma BQ, Ma LL, Ma XH, Mao JR, Masood A, Min Z, Mitthumsiri W, Nan YC, Ou ZW, Pang BY, Pattarakijwanic… See abstract for full author list ➔ Cao Z, et al. Among authors: zhang l, zhang hm, zhang r, zhang f, zhang sr, zhang jl, zhang bb, zhang pp, zhang ss, zhang pf, zhang xp, zhang sb, zhang lx, zhang yf, zhang yl, zhang x, zhang hy, zhang y. Phys Rev Lett. 2022 Dec 23;129(26):261103. doi: 10.1103/PhysRevLett.129.261103. Phys Rev Lett. 2022. PMID: 36608208
Prognostic factors of childhood acute lymphoblastic leukemia with TCF3::PBX1 in CCCG-ALL-2015: A multicenter study.
Zhang H, Wan Y, Wang H, Cai J, Yu J, Hu S, Fang Y, Gao J, Jiang H, Yang M, Liang C, Jin R, Tian X, Ju X, Hu Q, Jiang H, Li Z, Wang N, Sun L, Leung AWK, Wu X, Qian X, Qian M, Li CK, Yang J, Tang J, Zhu X, Shen S, Zhang L, Pui CH, Zhai X. Zhang H, et al. Among authors: zhang l. Cancer. 2023 Jun 1;129(11):1691-1703. doi: 10.1002/cncr.34741. Epub 2023 Mar 21. Cancer. 2023. PMID: 36943767
Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.
Chen L, Rangel JDG, Cil T, Li X, Cicin I, Shen Y, Liu Z, Ozyilkan O, Igor B, Chen J, Oleksandr K, Chen Z, Zhang H, Fu Z, Dong Q, Song S, Yu JC, Zhang L. Chen L, et al. Among authors: zhang l, zhang h. Cancer Med. 2023 Nov;12(22):20847-20863. doi: 10.1002/cam4.6664. Epub 2023 Nov 7. Cancer Med. 2023. PMID: 37935428 Free PMC article. Clinical Trial.
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).
Yang Y, Pan J, Wang H, Zhao Y, Qu S, Chen N, Chen X, Sun Y, He X, Hu C, Lin L, Yu Q, Wang S, Wang G, Lei F, Wen J, Yang K, Lin Z, Guo Y, Chen S, Huang X, Wu Y, Liang L, Chen C, Bai F, Ma X, Zhang Y, Leaw S, Zhang L, Fang W. Yang Y, et al. Among authors: zhang l, zhang y. Cancer Cell. 2023 Jun 12;41(6):1061-1072.e4. doi: 10.1016/j.ccell.2023.04.014. Epub 2023 May 18. Cancer Cell. 2023. PMID: 37207654 Free article. Clinical Trial.
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.
Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, Zhuang W, Zhao Y, Zhou M, Zhang W, Zhang Y, Wan Y, Li W, Song W, Wang ZM, Li B, Xia M, Yang Y, Fang W, Huang Y, Zhang L. Zhao Y, et al. Among authors: zhang l, zhang w, zhang y. EClinicalMedicine. 2023 Aug 3;62:102106. doi: 10.1016/j.eclinm.2023.102106. eCollection 2023 Aug. EClinicalMedicine. 2023. PMID: 37593227 Free PMC article.
125,012 results
You have reached the last available page of results. Please see the User Guide for more information.